DSpace@İnönü

Yazar "Laestadius, F" için listeleme

Yazar "Laestadius, F" için listeleme

Sırala: Sıra: Sonuçlar:

  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients 
    Petrylak, DP; de Wit, R; Chi, KN; Drakaki, A; Sternberg, CN; Nishiyama, H; Castellano, D; Hussain, S; Flechon, A; Bamias, A; Yu, EY; van der Heijden, MS; Matsubara, N; Alekseev, B; Necchi, A; Geczi, L; Ou, YC; Coskun, HS; Su, WP; Hegemann, M; Percent, IJ; Lee, JL; Tucci, M; Semenov, A; Laestadius, F; Peer, A; Tortora, G; Safina, S; del Muro, XG; Rodriguez-Vida, A; Cicin, I; Harputluoglu, H; Widau, RC; Liepa, AM; Walgren, RA; Hamid, O; Zimmermann, AH; Bell-McGuinn, KM; Powles, T (2017)
    Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel ...
  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients 
    Petrylak, DP; de Wit, R; Chi, KN; Drakaki, A; Sternberg, CN; Nishiyama, H; Castellano, D; Hussain, S; Flechon, A; Bamias, A; Yu, EY; van der Heijden, MS; Matsubara, N; Alekseev, B; Necchi, A; Geczi, L; Ou, YC; Coskun, HS; Su, WP; Hegemann, M; Percent, IJ; Lee, JL; Tucci, M; Semenov, A; Laestadius, F; Peer, A; Tortora, G; Safina, S; del Muro, XG; Rodriguez-Vida, A; Cicin, I; Harputluoglu, H; Widau, RC; Liepa, AM; Walgren, RA; Hamid, O; Zimmermann, AH; Bell-McGuinn, KM; Powles, T (2017)
    Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel ...
  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients 
    Petrylak, DP; de Wit, R; Chi, KN; Drakaki, A; Sternberg, CN; Nishiyama, H; Castellano, D; Hussain, S; Flechon, A; Bamias, A; Yu, EY; van der Heijden, MS; Matsubara, N; Alekseev, B; Necchi, A; Geczi, L; Ou, YC; Coskun, HS; Su, WP; Hegemann, M; Percent, IJ; Lee, JL; Tucci, M; Semenov, A; Laestadius, F; Peer, A; Tortora, G; Safina, S; del Muro, XG; Rodriguez-Vida, A; Cicin, I; Harputluoglu, H; Widau, RC; Liepa, AM; Walgren, RA; Hamid, O; Zimmermann, AH; Bell-McGuinn, KM; Powles, T (2017)
    Background Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel ...
  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients 
    Petrylak, DP; de Wit, R; Chi, KN; Drakaki, A; Sternberg, CN; Nishiyama, H; Castellano, D; Hussain, SA; Flechon, A; Bamias, A; Yu, EY; van der Heijden, MS; Matsubara, N; Alekseev, B; Necchi, A; Geczi, L; Ou, YC; Coskun, HS; Su, WP; Bedke, J; Gakis, G; Percent, IJ; Lee, JL; Tucci, M; Semenov, A; Laestadius, F; Peer, A; Tortora, G; Safina, S; del Muro, XG; Rodriguez-Vida, A; Cicin, I; Harputluoglu, H; Tagawa, ST; Vaishampayan, U; Aragon-Ching, JB; Hamid, O; Liepa, AM; Wijayawardana, S; Russo, F; Walgren, RA; Zimmermann, AH; Hozak, RR; Bell-McGuinn, KM; Powles, T (2020)
    Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, ...
  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients 
    Petrylak, DP; de Wit, R; Chi, KN; Drakaki, A; Sternberg, CN; Nishiyama, H; Castellano, D; Hussain, SA; Flechon, A; Bamias, A; Yu, EY; van der Heijden, MS; Matsubara, N; Alekseev, B; Necchi, A; Geczi, L; Ou, YC; Coskun, HS; Su, WP; Bedke, J; Gakis, G; Percent, IJ; Lee, JL; Tucci, M; Semenov, A; Laestadius, F; Peer, A; Tortora, G; Safina, S; del Muro, XG; Rodriguez-Vida, A; Cicin, I; Harputluoglu, H; Tagawa, ST; Vaishampayan, U; Aragon-Ching, JB; Hamid, O; Liepa, AM; Wijayawardana, S; Russo, F; Walgren, RA; Zimmermann, AH; Hozak, RR; Bell-McGuinn, KM; Powles, T (2020)
    Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, ...
  • Ramucirumab plus docetaxel versus placebo plus docetaxel in patients 
    Petrylak, DP; de Wit, R; Chi, KN; Drakaki, A; Sternberg, CN; Nishiyama, H; Castellano, D; Hussain, SA; Flechon, A; Bamias, A; Yu, EY; van der Heijden, MS; Matsubara, N; Alekseev, B; Necchi, A; Geczi, L; Ou, YC; Coskun, HS; Su, WP; Bedke, J; Gakis, G; Percent, IJ; Lee, JL; Tucci, M; Semenov, A; Laestadius, F; Peer, A; Tortora, G; Safina, S; del Muro, XG; Rodriguez-Vida, A; Cicin, I; Harputluoglu, H; Tagawa, ST; Vaishampayan, U; Aragon-Ching, JB; Hamid, O; Liepa, AM; Wijayawardana, S; Russo, F; Walgren, RA; Zimmermann, AH; Hozak, RR; Bell-McGuinn, KM; Powles, T (2020)
    Background Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonistplus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, ...